Practical Applicability of the ISARIC-4C Score on Severity and Mortality Due to SARS-CoV-2 Infection in Patients with Type 2 Diabetes

Oana Albai 1,2,3, Mirela Frandes 4,* , Alexandra Sima 1,2 , Bogdan Timar 1,2,3, Adrian Vlad 1,2,3 and Romulus Timar 1,2,3

1 Department of Internal Medicine-Diabetes, Nutrition, Metabolic Diseases and Systemic Rheumatology, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania; albai.oana@umft.ro (O.A.); sima.alexandra@umft.ro (A.S.); timar.bogdan@umft.ro (B.T.); vlad.adrian@umft.ro (A.V.); timar.romulus@umft.ro (R.T.)
2 Department of Diabetes and Metabolic Diseases, “Pius Brinzeu” Emergency Hospital, 300182 Timisoara, Romania
3 Centre for Molecular Research in Nephrology and Vascular Disease/MOL-NEPHER-VASC, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
4 Department of Functional Sciences—Medical Informatics and Biostatistics, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania

* Correspondence: mirela.frandes@umft.ro

Abstract: Background and objectives. There is a bidirectional relationship between SARS-CoV-2 infection and diabetes mellitus (DM), as people with DM are more vulnerable, and SARS-CoV-2 infections worsen the prognosis in these patients. The main purpose of the study was to evaluate the application validity of the ISARIC-4C score in patients confirmed with SARS-CoV-2 infection. Materials and Methods. The study included 159 patients previously known to have type 2 DM and confirmed positive for SARS-CoV-2 infection. We analyzed the concordance between the clinical evaluation of the patients and the ISARIC-4C score. Results. The mortality rate in hospitalized patients was 25.15%. The mortality risk was higher for ISARIC-4C values >14 than in the opposite group (63.93% vs. 31.24%; p < 0.001). The area under the curve (AUC) of the mortality score was 0.875 (95% CI: 0.820–0.930; p < 0.001), correctly classifying 77.36% of the cohort. A cut-off value of >14 had a sensitivity of 87.80% (95% CI: 87.66–87.93), specificity 73.72% (95% CI: 73.48–73.96), positive predictive value 53.73% (95% CI: 53.41–54.04), and negative predictive value 94.56% (95% CI: 94.5–94.62). The Cox regression model showed that the length of hospitalization (LH) was significantly influenced by body mass index, lung impairment, and aspartate aminotransferase, increasing the hazards, while lower HbA1c and lower SatO2 significantly decreased the hazards. Conclusions. ISARIC-4C score estimates the likelihood of clinical deterioration and the mortality risk in patients hospitalized with type 2 DM and positive for SARS-CoV-2, being useful in assessing the prognosis from the onset, as well as in developing therapeutic strategies.

Keywords: SARS-CoV-2 infection; ISARIC-4C score; diabetes mellitus; risk; severity; mortality

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection emerged in December 2019 in the city of Wuhan, from where it spread around the world, creating a pandemic. There are currently over 450 million cases worldwide and over 6 million deaths [1]. Patients with diabetes mellitus (DM) are vulnerable, both physically and psychologically, and are much more prone to infections [2]. Unsatisfactory glycemic control, chronic complications, other associated comorbidities, and cardiovascular risk factors (CVRs) have been shown to increase the risk of SARS-CoV-2 infection 2–3-fold in patients with DM [3,4]. DM is a condition involving the immune and cardiovascular systems,
and it is associated with various disorders of platelet function and clotting, making the body vulnerable to SARS-CoV-2. Moreover, the presence of comorbidities (e.g., high blood pressure, obesity, ischemic cardiomyopathy) and specific complications of DM (cardiovascular events, such as myocardial infarction, stroke, renal failure, lower limb arteriopathy) negatively influence the course of the infectious disease [5–10].

SARS-CoV-2 is an RNA virus that has 82% homology to the human SARS-CoV virus that causes severe acute respiratory syndrome (SARS) [11]. It is a single-stranded RNA virus consisting of four structural proteins, namely, spike glycoprotein (S), an envelope protein (E), membrane protein (M) and nucleocapsid (N). SARS-CoV-2 glycoprotein S allows the virus to enter host cells using the angiotensin-converting enzyme 2-ACE2 receptor. ACE2 receptors are found in large amounts in the respiratory tract and lung parenchyma, as well as in key metabolic organs (e.g., muscle, liver, endocrine pancreas, fat tissue), which play an important role in glucose homeostasis. The known spike protein of the coronavirus could attack and destroy β-pancreatic cells, like DM [12–14]. Thus, the SARS-CoV-2 infection causes altered insulin secretion by impaired β-pancreatic cell function or inflammation-induced insulin resistance, with the triggering of pleiotropic effects that affect glucose metabolism, exacerbating a pre-existing DM or triggering de novo DM [15].

Infection with SARS-CoV-2 is accompanied by the release of excessive amounts of proinflammatory cytokines and chemokines: interferon, TNF-alpha, interleukins 1beta, 6, 12, 18, 33, and others, which trigger a violent immune response against the lungs (causing acute respiratory distress syndrome (ARDS)) and other organs (leading to multiple organ failure), which rapidly progress to death. Moreover, increased levels of IL6 and lactate dehydrogenase (LDH) are direct indicators of disease severity [16,17]. Moreover, patients with coronavirus disease (COVID-19) show increased values of other inflammatory markers (D-Dimers, ferritin) that contribute to an increased risk of micro and macrovascular complications. Glycemic deterioration is a complication of COVID-19, with SARS-CoV-2 infection requiring significant dose increases in insulin-treated patients [18]. These changes appear to be associated with pro-inflammatory cytokine levels [19]. Although diabetic ketoacidosis (DKA) is a more common acute metabolic complication in type 1 DM, case analysis has shown that approximately 77% of SARS-CoV-2-associated DKA infections occurred in patients with type 2 DM [20].

The ISARIC-4C score (4C Mortality Score and 4C Deterioration models) represents risk stratification tools that predict in-hospital mortality or in-hospital clinical deterioration. It is designed to be easy to use, requiring only parameters that are commonly available at hospital admission. The ISARIC-4C score took into consideration the following variables: nosocomial (defined as the onset of symptoms or the first positive SARS-CoV-2), sex, number of comorbidities (chronic heart disease; chronic respiratory diseases-excluding asthma; chronic kidney disease-estimated glomerular filtration rate ≤30; mild to severe liver disease; dementia; chronic neurological disorders; connective tissue disease; diabetes mellitus-diet, tablet or insulin-controlled; HIV-AIDS; malignancy; obesity), radiographic chest infiltrates, receiving oxygen (when oxygen saturation measured), Glasgow coma scale (<15 or >15), age (years), respiratory rate (breaths/min), admission oxygen saturation (%), urea (mmol/L), CRP (mg/L), lymphocytes ($\times 10^9$/L) [21].

The main purpose of this study was to evaluate the validity of the ISARIC-4C score application in patients with type 2 DM, confirmed with SARS-CoV-2 infection and hospitalized at the emergency department. We analyzed the concordance between the clinical evaluation and the ISARIC-4C score, following other risk factors that may influence the prognosis of these patients.

2. Material and Methods
2.1. Study Design and Patients

The study included 159 patients admitted to “Pius Brînzeu” County Hospital in Timisoara through the emergency department, from 1 December 2020 to 1 March 2021. Patients were previously known for having type 2 DM. After coming to the emergency department...
room, patients were confirmed positive for SARS-CoV-2 infection and admitted to the special ward for COVID-19 patients with DM. Patients who died in the first 14 days after admission were classified as non-survivors. The exclusion criteria were under age 18-year-old patients, patients with severe psychiatric disorders and patients who presented major acute cardiovascular events. The diagram representing the process of the ISARIC-4C score application is presented in Figure 1.

![Diagram representing the process of the ISARIC-4C score application.](image)

**Figure 1.** Diagram representing the process of the ISARIC-4C score application.

This study was conducted in accordance with the Declaration of Helsinki, and the protocol of our study was approved by the Ethics Committee of the Emergency County Hospital Timisoara (Approval number: 164/16 November 2020). All patients included in the study provided written informed consent for the acquisition, analysis, and publication of the anonymous data collected during their hospital admission.

### 2.2. Clinical, Anthropometric, and Laboratory Data

What was collected: demographics, family history and past medical history, associated malignancies, clinical and paraclinical investigations, and treatment administered. Evaluation of glycemic control was performed by inspecting fasting, postprandial glycaemia and HbA1c. The lipid panel (e.g., CT, TG, HDLc, LDLc) was also assessed. The presence of DM-related complications was also investigated: microangiopathic (e.g., diabetic retinopathy, diabetic renal disease), macroangiopathic (e.g., ischemic heart disease,
diabetic arteriopathy, neurovascular damage), as well as neuropathic ones. Patients were interviewed and the presence of previously known associated pulmonary pathology was noted (e.g., chronic obstructive pulmonary disease, bronchial asthma, bronchopulmonary cancer). For assessing the degree of lung damage, all patients underwent a pulmonary CT scan, both at admission and at discharge.

Clinical parameters (e.g., blood pressure, heart rate, respiratory rate, oxygen saturation—SatO2, temperature, diuresis), as well as paraclinical parameters (e.g., C-reactive protein—CRP, fibrinogen, complete blood count, D-Dimer, liver tests—ASAT, ALAT, serum ferritin, urea, creatinine) were dynamically monitored.

A thorough history was taken, specifying the exact reasons for admission (e.g., cough, myalgia, headache, odynophagia, muscle weakness, fever, chills, nausea, vomiting, diarrhea, etc.).

2.3. Confirmation of SARS-CoV-2 Infection

For the detection of SARS-CoV-2, we used the reference test known as SARS-CoV-2 viral RNA, which uses the Real-Time PCR method (RT-PCR). Polymerase chain reaction (PCR) detects the virus through techniques of amplification of viral genetic material. Samples from the upper respiratory tract (nasal and pharyngeal exudate) were collected, preferably together with blood and other samples from the lower respiratory tract (sputum or bronchial alveolar lavage—in case of severe disease). From these samples, viral identification is performed by the RT-PCR method. The sample is considered positive if two coronavirus-specific gene fragments are detected, one of which is specific to SARS-CoV-2.

The clinical forms of SARS-CoV-2 infection are: Mild form: patient with any signs and symptoms (fever, cough, sore throat, malaise, headache, muscle aches) without difficulty breathing, dyspnea or abnormal chest images (without pneumonia). Moderate form: patient with fever and signs of non-severe pneumonia, without the need for additional oxygen. Severe form: patient with signs of severe pneumonia. Severe adult pneumonia: suspected, probable, or confirmed case of COVID 19, plus one of the following: • severe dyspnea (FR ≥ 30/min); • hypoxemia (SpO2 ≤ 94% at rest); • PaO2/FiO2 ≤ 300 mmHg; • rapid negative evolution of the lung imaging pattern in the last 24–48 h by ≥50%; • progressive decrease in the number of peripheral lymphocytes and rapid increase in lactate. Critical form: patients with COVID-19 and one or more of the following: ARDS; shock; any organ failure that requires care in the intensive care unit; other conditions with major danger to the patient’s life.

2.4. ISARIC-4C Score

The severity was assessed by computing the ISARIC-4C score, which aids the clinician in making therapeutic decisions. The ISARIC score allows objective assessment of severity and risk of death based on clinical and paraclinical characteristics. It is a risk stratification score of mortality or deterioration of clinical status. Herein, clinical deterioration means the need for ventilatory support, critical care in an intensive care unit, or death.

The computation of the ISARIC-4C score includes the following parameters: age, gender, number of present comorbidities, lung impairment, O2 requirement, Glasgow score, respiratory rate/min, O2 saturation, serum urea, C-reactive protein, lymphocyte count (score range 0–21 points) [21].

2.5. Statistical Analysis

The data were described by computing the mean ± standard deviation for continuous variables and the frequency (percentage) for nominal variables. A comparison of survivor and non-survivor groups was made considering the type of variables. Continuous variables were compared using the t-test or Wilcoxon rank-sum test, while nominal variables were compared using the chi-square or Fisher’s exact test. The normality of continuous variable was tested using the Kolmogorov–Smirnov’s test.
We analyzed the mortality rate by plotting the Receiver Operator Characteristic (ROC) curve using the ISARIC-4C score as the classification variable. We presented the ROC curve together with the significance level $p$. Applying Youden’s index criterion, we determined the optimal cut-off value we used in the mortality analysis.

Kaplan–Meier survival curves were presented for the days of hospitalization of each risk group based on the ISARIC-4C score. A Cox proportional hazards regression model was derived to assess the effect of risk factors on the length of hospitalization. We entered the variables which were previously identified as being significantly different in the group of survivors compared with non-survivors into the model. We compared the days of hospitalization of each risk group considering the hazard ratios (HR) computed by the Cox regression model. Harrell’s C-index, the concordance index, was used as a goodness of fit measure for models.

The statistical analysis was performed with MedCalc® Statistical Software version 20.106 (MedCalc Software Ltd., Ostend, Belgium). The significance threshold was considered $p$-value $< 0.05$.

3. Results

3.1. Characteristics of Patients

In the study period (1st December 2020 to 1st March 2021), 159 admissions of COVID-19 confirmed cases were recorded through the emergency room. On the 159 patients included in the study, 85 were male (53.45%), and 74 were female (46.55%). Patients were previously diagnosed with type 2 DM. The mean age was 68.05 ± 10.06 years, and the average duration of DM was 9.98 ± 4.71 years. The general characteristics of the patients are presented in Table 1.

A percentage of 25.15% were hospital deaths. The mortality score was 13.66 ± 3.19, while the death risk was 45% ± 19.15. The deterioration score was 633.68 ± 159.83, while the deterioration risk was 67.37% ± 19.09.

The age of survivors was significantly lower than non-survivors (65.20 ± 8.75 vs. 70.90 ± 9.30; $p = 0.010$). Moreover, significant differences were noticed for SatO₂, lung damage, respiratory rate, PCR, D-dimers, ASAT, ALAT, urea.

Hypertension has been identified in almost all patients: 157 patients (98.74%). Of these, 48.42% presented Hypertension grade II and 50.31% grade III. Cardiac pathology (pectoris angina, atrial fibrillation, heart failure) was present in 152 patients (95.59%). Moreover, 32 patients (20.12%) had a history of lung disease (chronic obstructive pulmonary disease, asthma) and 6 patients (3.77%) had a known neoplasm. Table 2 shows the associated comorbidities.
Table 1. General characterization of patients: anthropometric parameters, lipidic and glycemic profiles at admission.

| Variable                          | All Cohort   | Survivors    | Non-Survivors | p-Value    |
|-----------------------------------|--------------|--------------|---------------|------------|
|                                   | (n = 159)    | (n = 117)    | (n = 42)      |            |
| Age (years)                       | 68.05 ± 10.06| 65.20 ± 8.75| 70.90 ± 11.30| 0.010      |
| Gender (Males)                    | 85 (53.45%)  | 63 (53.4%)   | 22 (53.7%)    | 0.976      |
| BMI (kg/m²)                       | 31.24 ± 4.31 | 30.34 ± 3.76| 32.14 ± 4.63 | 0.0134     |
| Duration of DM (years)            | 9.98 ± 4.71  | 9.76 ± 4.45  | 10.20 ± 4.98 | 0.5947     |
| Mean HbA1c (%)                    | 9.02 ± 1.06  | 8.84 ± 0.78  | 9.20 ± 1.36  | 0.0394     |
| Mean blood sugar at admission (mg/dL) | 228.97 ± 106.56 | 211.19 ± 104.98 | 246.75 ± 114.43 | 0.0675     |
| Serum cholesterol (mg/dL)         | 206.01 ± 39.08| 200.88 ± 37.23| 211.14 ± 40.19| 0.1351     |
| Serum triglycerides (mg/dL)       | 245.43 ± 117.68| 214.52 ± 114.34| 276.34 ± 119.76| 0.0034     |
| HDLc (mg/dL)                      | 36.62 ± 12.64| 38.17 ± 13.88| 35.06 ± 54.12| 0.5654     |
| LDLc (mg/dL)                      | 121.36 ± 32.81| 119.80 ± 35.17| 122.92 ± 37.56| 0.6284     |
| Fever                             | 151 (94.96%) | 112 (94.9%)  | 39 (95.1%)    | 0.838      |
| Dyspnea                           | 157 (98.74%) | 118 (100%)   | 39 (95.1%)    | 0.016      |
| Myalgia                           | 142 (89.3%)  | 103 (87.3%)  | 39 (95.1%)    | 0.132      |
| Diarrhea                          | 10 (6.28%)   | 4 (3.4%)     | 6 (14.6%)     | 0.019      |
| Nausea/vomiting                   | 9 (5.66%)    | 6 (5.1%)     | 3 (7.3%)      | 0.422      |
| SatO₂ (%)                         | 84.93 ± 8.26 | 93.53 ± 8.43 | 76.33 ± 5.72  | <0.001     |
| Lung impairment (%)               | 48.83 ± 17.73| 43.55 ± 11.31| 54.11 ± 18.86| <0.001     |
| Respiratory rate-RR               | 30.18 ± 4.93 | 28.07 ± 3.74 | 32.29 ± 5.01  | <0.001     |
| PCR                               | 157.41 ± 81.56| 100.09 ± 52.96| 214.73 ± 94.17| <0.001     |
| D-Dimer                           | 1257.79 ± 142.06| 925.97 ± 115.98| 1589.61 ± 193.92| <0.001     |
| ASAT                              | 53.91 ± 24.71| 44.73 ± 20.22| 63.09 ± 30.98| <0.001     |
| ALAT                              | 57.46 ± 51.90| 44.21 ± 17.03| 70.71 ± 96.23| <0.001     |
| Lymphocytes                       | 983.90 ± 538.36| 896.34 ± 443.51| 1071.46 ± 739.02| 0.112      |
| Low platelets                     | 294,981 ± 96,013.54| 300,762.71 ± 95,017.82| 278,341.46 ± 98,097.05| 0.226     |
| Urea                              | 52.40 ± 31.67| 47.11 ± 23.06| 57.69 ± 45.68 | <0.001     |
| Mortality score                   | 13.66 ± 3.19 | 12.63 ± 2.94 | 14.69 ± 1.74 | <0.001     |
| Risk of death (%)                 | 45.18 ± 19.15| 38.72 ± 16.84| 51.64 ± 11.98| <0.001     |
| Deterioration score               | 633.68 ± 159.83| 610.42 ± 108.65| 656.94 ± 162.76| <0.001     |
| Risk of deterioration (%)         | 67.37 ± 19.09| 59.56 ± 15.58| 75.18 ± 5.70 | <0.001     |
| ICM/OTI                           | 42 (26.4%)   | 2 (1.7%)     | 40 (97.6%)    | <0.001     |

Abbreviations: BMI, body mass index; HDLc, HDL cholesterol; LDLc, LDL cholesterol; SatO₂, oxygen saturation; PCR, C-reactive protein; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; ICM/OTI, intensive care measures/oro-tracheal intubation.
Table 2. Associated comorbidities.

| Comorbidity | Type                                      | Value              |
|-------------|-------------------------------------------|--------------------|
| Hypertension| Grade II                                  | 77 (48.42%)        |
|             | Grade III                                 | 80 (50.31%)        |
| Neoplasm    | Breast cancer                             | 1 (0.62%)          |
|             | Melanoma                                  | 1 (0.62%)          |
|             | Laryngeal cancer                          | 1 (0.62%)          |
|             | Bronchopulmonary neoplasm                 | 1 (0.62%)          |
|             | Prostate cancer                           | 1 (0.62%)          |
|             | Gastric neoplasm                          | 1 (0.62%)          |
| Heart Disease| Chronic coronary heart disease: pectoris, angina, atrial fibrillation, heart failure | 152 (95.59%) |
| Lung disease| Chronic obstructive pulmonary disease      | 20 (12.57%)        |

Asthma 9 (5.66%)

Note: Hypertension Grade II: 160–179/100–109 mmHg, Hypertension Grade III: ≥180/≥110 mmHg. Heart disease: angina pectoris, arrhythmias, heart failure. Lung disease: chronic obstructive pulmonary disease, asthma.

3.2. Accuracy of the ISARIC-4C Score

The ROC curve of the mortality score had AUC of 0.875 (95% CI: 0.820–0.930; \( p < 0.001 \)) (Figure 2).

![Mortality score](image)

Figure 2. Receiver-operating characteristics (ROC) analysis of the mortality score. Abbreviations: AUC, Area under the curve.

Applying the Youden’s index, we identified the optimal cut-off value of the ISARIC score as > 14. The sensitivity associated with the optimal cut-off score >14 was 87.80% (95% CI: 87.66–87.93), the specificity was 73.72% (95% CI: 73.48–73.96), while the predictive values (PV) were positive PV of 53.73% (95% CI: 53.41–54.04), and negative PV of 94.56% (95% CI: 94.5–94.62).

When grouping the cohort according to the ISARIC cut-off score, we observed a higher mortality score for values >14 than in the group with scores equal or less than 14 (16.49 vs. 11.61; \( p < 0.001 \)). Moreover, the mortality risk was higher for ISARIC values > 14 than in the group with scores equal or less than 14 (62.67% vs. 32.01%; \( p < 0.001 \)).
When considering the deterioration, we observed a higher deterioration score for ISARIC values > 14 than in the opposite group (744.42 vs. 532.22; \( p < 0.001 \)). The deterioration risk was also higher for ISARIC values > 14 than in the opposite group (82.08 vs. 54.83; \( p < 0.001 \)). A percent of 87.8% of patients with ISARIC scores higher than 14 were non-survivors vs. 12.2% of patients with ISARIC scores less than 14 were non-survivors (\( p < 0.001 \)). Most of the patients with ISARIC scores higher than 14 were at ICM/OTI (85.7%), while 14.3% of patients with ISARIC scores less than 14 were at ICM/OTI (14.3%) (\( p < 0.001 \)).

### 3.3. Hospitalization Rate

We compared the days of hospitalization among survivors for the intermediate (scores: 4–8), high (scores: 9–14), and very high-risk (scores: \( \geq 15 \)) groups by the ISARIC-4C mortality score (Figure 3).

![Kaplan–Meier curve of hospitalization days in surviving patients grouped by the ISARIC-4C risk.](image-url)

The mean of hospitalization days for the intermediate-risk group was 12 days (95% CI: 12.00–12.00), while for the high-risk and very high-risk groups it was 22.88 days (95% CI: 21.91–23.85), and 17.16 days (15.39–18.93). We observed a significant difference between the hospitalization days of the risk groups (Log-rank test \( \chi^2(2) = 25.593, \ p < 0.001 \)). The high-risk group had a significantly lower HR = 0.151 (95% CI: 0.081–0.282) for discharge than the intermediate-risk group, while in the very high-risk group the HR was 6.612 (95% CI: 3.543–12.338).

The overall model fit of the Cox regression showed a significant relationship between the days of hospitalization and the covariates in the model (Chi-square test \( \chi^2(12) = 136.075, \ p < 0.001 \)). The Harrell’s C-index was 0.878 (95% CI: 0.842–0.914) indicating that the model is good at predicting which patients will require a longer length of hospitalization. The multivariate Cox regression analysis showed that age did not influence the days of hospitalization, HR = 0.981 (95% CI: 0.921–1.046). We observed that BMI had significantly influenced the days of hospitalization increasing the hazard, HR = 1.183 (95% CI: 1.015–1.381). On the contrary, a lower mean of HbA1c significantly influenced the days of hospitalization lowering the hazard, HR = 0.641 (95% CI: 0.492–0.835) (Table 3).
Table 3. Factors influencing the length of hospitalization.

| Covariate                  | b   | SEE  | Wald | HR   | 95% CI          | p-Value |
|----------------------------|-----|------|------|------|-----------------|---------|
| Age (years)                | −0.018 | 0.032 | 0.312 | 0.981 | 0.921–1.046     | 0.576   |
| BMI (kg/m²)                | 0.168 | 0.078 | 4.632 | 1.183 | 1.015–1.381     | 0.031   |
| HbA1c (%)                  | −0.443 | 0.135 | 10.821 | 0.641 | 0.492–0.835     | 0.001   |
| Triglycerides (mg/dL)      | 0.001 | 0.002 | 0.136 | 1.001 | 0.995–1.006     | 0.712   |
| Lung impairment (%)        | 0.072 | 0.022 | 10.397 | 1.075 | 1.029–1.124     | 0.001   |
| SatO₂ (%)                  | −0.138 | 0.034 | 16.081 | 0.871 | 0.814–0.932     | <0.001  |
| PCR                        | 0.004 | 0.002 | 2.803 | 1.004 | 0.999–1.011     | 0.094   |
| ASAT                       | −0.006 | 0.011 | 0.412 | 0.993 | 0.973–1.014     | 0.521   |
| ALAT                       | 0.011 | 0.004 | 5.882 | 1.011 | 1.002–1.021     | 0.015   |
| D-Dimer                    | 0.001 | 0.001 | 0.391 | 1.001 | 0.999–1.004     | 0.532   |
| Urea                       | −0.008 | 0.005 | 2.681 | 0.991 | 0.981–1.002     | 0.101   |

Abbreviations: b, regression coefficient; SEE, standard error; Wald, Wald statistic (b/SE)²; HR, hazards ratio; 95% CI, 95% confidence interval for HR; BMI, body mass index; SatO₂, oxygen saturation; PCR, C-reactive protein; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase.

The lung impairment significantly influenced the days of hospitalization increasing the hazard, HR = 1.075 (95% CI: 1.029–1.124). In addition, SatO₂ significantly influenced the days of hospitalization lowering the hazard, HR = 0.871 (95% CI: 0.814–0.932). Moreover, ALAT significantly influenced the days of hospitalization increasing the hazard, HR = 1.011 (95% CI: 1.002–1.021).

4. Discussion

Patients with DM, especially those with poor glycemic control and chronic complications are at higher risk of becoming infected with the SARS-CoV-2 virus and developing severe forms of the disease. Since the beginning of the pandemic, DM has been reported as one of the increased risk factors responsible for the rapid progression and poor prognosis of COVID-19 [22]. In general, patients with DM have a higher susceptibility to infectious diseases such as tuberculosis, pneumonia, or influenza. The mechanisms involved are not completely known, but it seems that an important role is played by chronic hyperglycemia, as the hyperglycemic environment is known to increase the virulence of some pathogens. Phagocytosis and chemotactic processes have been shown to be impaired, and the T-cell, neutrophil responses and interleukin secretion are reduced [22–25].

We report an ISARIC-4C score > 14 as an indicator of higher mortality risk in patients hospitalized with type 2 DM and positive for SARS-CoV-2. The mortality rate in our group was 25.15%, the mean age being statistically significantly higher in patients who died, compared to survivors: 70.90 ± 9.30 years versus 65.20 ± 8.75 years (p = 0.010). In our group, patients were previously known with type 2 DM, with a mean duration of disease of 9.98 ± 4.71 years. We also found a rather high value for mean blood sugar at admission, 228.97 ± 106.56 mg/dL.

Yang et al. compared data from over 400 patients and found that serum levels of fasting blood glucose were higher in patients with SARS than in patients with pneumonia without SARS. Moreover, 21.5% of patients who had a poor outcome of SARS infection had a history of DM, a significantly higher percentage than those who recovered (3.9%) [16]. A study conducted in Wuhan showed that of 26 deaths caused by SARS-CoV-2, 42.3% had DM [26]. Another study showed that COVID-19-related death was associated with being male (hazard ratio (HR) 1.59 (95% confidence interval 1.53–1.65)), greater age and deprivation (both with a strong gradient), diabetes, severe asthma, and various other medical conditions. Compared with people of white ethnicity, black and south Asian people were at higher risk, even after adjustment of other factors (HR 1.48 (1.29–1.69) and
Another cohort study that looked at 201 patients in Wuhan with confirmed COVID-19 pneumonia showed that 10.9% of patients had DM. They also noted that among the patients who developed ARDS (41.8%), DM was the 2nd most common comorbidity (19.0% in ARDS patients versus 5.1% in non-ARDS patients) [28].

Kulcsar et al. studied the severity of MERS-CoV infection in a group of mice in which DM was induced by a high-fat diet [29]. Results showed a more severe and prolonged acute phase of infection in mice with DM with altered recruitment of lung CD4+ T cells and altered secretion of cytokines particularly increased IL17. A similar immune response is observed in patients with COVID-19, with reduced CD4+ T cell counts and increased Th17 cell counts. It is known that the production of IL2 decreases with age, which favors the differentiation of CD4+ T cells into Th17 [30]. Moreover, this inflammatory profile may explain the severity of SARS-CoV-2 infection in patients with DM [31].

A multicenter retrospective study conducted in China has shown that fasting blood sugar \( \geq 126 \text{ mg/dL} \) at admission was an independent predictor of increased mortality in patients with COVID-19 without DM [32]. Severe acute respiratory syndrome from SARS-CoV-2 infection results in tissue hypoxia with interstitial lung injury and acute respiratory distress syndrome [33]. Patients with DM and COVID-19 have a higher risk of clinical deterioration and faster progression to cardiorespiratory failure precisely because of increased oxidative stress, cytokine production and endothelial dysfunction. All these characteristic changes in patients with DM are accompanied by higher thromboembolic risk and faster deterioration of vital organs [34–38].

Among all patients under observation, the percentage of those presenting respiratory manifestations (dyspnea, irritative cough, headache, myalgia, fever) was significantly higher than those presenting digestive symptomatology at onset (nausea, vomiting, diarrhea). Most of the patients had hypertension or another cardiac pathology. Using the ISARIC-4C score to assess the risk of clinical deterioration, as well as the risk of mortality, we identified a cut-off value of 14: the sensitivity associated with this value was 87.80% and the specificity 73.72%.

A limitation of our study is that we included the evaluation of the ISARIC-4C score performance, without testing the efficiency of an individualized treatment based on this score. Moreover, patients without DM or patients newly diagnosed with DM were not included. The strengths of our study include the chosen population, i.e., patients with DM, who present complex and diverse pathology with a high risk of multiple complications. Therefore, applying a prognostic score is of great importance.

5. Conclusions

Patients with DM need close and careful monitoring to ensure optimal glycemic control, thus preventing major metabolic imbalances, such as diabetic ketoacidosis, or other complications, both acute and chronic. This appears to be the solution to prevent clinical deterioration and poor prognosis in the case of patients with COVID-19. In the studied group, the application of the ISARIC-4C score was useful for assessing the prognosis from the moment of hospitalization and the mortality risk in patients hospitalized with type 2 DM and positive for SARS-CoV-2, being useful in developing therapeutic strategies.

**Author Contributions:** Conceptualization O.A. and R.T.; Methodology M.F.; Software, M.F. and B.T.; Validation, O.A., R.T. and A.V.; Formal Analysis, M.F.; Investigation, O.A., A.S. and A.V.; Resources, A.S., B.T. and A.V.; Data Curation, A.S., B.T. and A.V.; Writing—Original Draft Preparation, O.A., A.S. and B.T.; Writing—Review & Editing, O.A., M.F. and B.T.; Visualization, B.T. and R.T.; Supervision, O.A. and R.T.; Project Administration, O.A.; Funding Acquisition, O.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** This study was conducted in accordance with the Declaration of Helsinki, and the protocol of our study was approved by the Ethics Committee of the Emergency County Hospital Timisoara (Approval number: 164/16 November 2020).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: The authors gratefully acknowledge the professionals from the Center for Diabetes Treatment of the “Pius Brinzeu” Emergency Hospital Timisoara, Romania, for their support in data acquisition.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. World Health Organization. Novel Coronavirus (2019-nCoV): Situation Report, 1; World Health Organization: Geneva, Switzerland, 2020. Available online: https://apps.who.int/iris/handle/10665/330760 (accessed on 1 January 2021).

2. Albia, O.; Frandes, M.; Timar, B.; Timar, R.; Anghel, T.; Anghel, V.F.; Sima, A. The Mental Status in Patients with Diabetes Mellitus Admitted to a Diabetes Clinic After Presenting in the Emergency Room: The Application of the SCL-90 Scale. Diabetes Metab. Syndr. Obes.-Targets Ther. 2021, 14, 1833–1840. [CrossRef] [PubMed]

3. Abu-Ashour, W.; Twells, L.K.; Valcour, J.E.; Gamble, J.M. Diabetes and the occurrence of infection in primary care: A matched cohort study. BMC Infect. Dis. 2018, 18, 67. [CrossRef] [PubMed]

4. Bartelink, M.; Hoek, L.; Freriks, J.; Rutten, G.E.H. Infections in patients with type 2 diabetes in general practice. Diabetes Res. Clin. Pract. 1998, 40, 15–19. [CrossRef]

5. Wynants, L.; Van Calster, B.; Collins, G.S.; Riley, R.D.; Heinze, G.; Schuit, E.; Bonten, M.M.J.; Dahly, D.L.; Damen, J.A.A.; Debray, T.P.A.; et al. Prediction models for diagnosis and prognosis of COVID-19 infection: Systematic review and critical appraisal. BMJ 2020, 369, m1328. [CrossRef] [PubMed]

6. Holman, N.; Knighton, P.; Kar, P.; O’Keefe, J.; Curley, M.; Weaver, A.; Barron, E.; Bakhai, C.; Khunti, K.; Wareham, N.J.; et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. Lancet Diabetes Endocrinol. 2020, 8, 823–833. [CrossRef]

7. Zhu, L.; She, Z.G.; Cheng, X.; Qin, J.J.; Zhang, X.J.; Cai, J.; Lei, F.; Wang, H.; Xie, J.; Wang, W.; et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020, 31, 1068–1077. [CrossRef]

8. Barron, E.; Bakhai, C.; Kar, P.; Weaver, A.; Bradley, D.; Ismail, H.; Knighton, P.; Holman, N.; Khunti, K.; Sattar, N.; et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol. 2020, 8, 813–822. [CrossRef]

9. Albia, O.; Frandes, M.; Timar, B.; Paun, D.-L.; Roman, D.; Timar, R. Long-term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome. Diabetes Metab. Syndr. Obes. Targets Ther. 2020, 13, 1317–1326. [CrossRef]

10. Albia, O.; Timar, B.; Paun, D.-L.; Sima, A.; Roman, D.; Timar, R. Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus. Diabetes Metab. Syndr. Obes. 2020, 13, 3873–3878. [CrossRef]

11. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020, 395, 507–513. [CrossRef]

12. Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D.; Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020, 181, 281–292.e6. [CrossRef]

13. Li, F.; Li, W.; Farzan, M.; Harrison, S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005, 309, 1864–1868. [CrossRef]

14. Zhang, H.; Penninger, J.M.; Li, Y.; Zhong, N.; Slutsky, A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020, 46, 586–590. [CrossRef] [PubMed]

15. Wu, L.; Girgis, C.M.; Cheung, N.W. COVID-19 and diabetes: Insulin requirements parallel illness severity in critically unwell patients. Clin. Endocrinol. 2020, 93, 390–393. [CrossRef] [PubMed]

16. Yang, J.K.; Feng, Y.; Yuan, M.Y.; Yuan, S.Y.; Fu, H.J.; Wu, B.Y.; Sun, G.Z.; Yang, G.R.; Zhang, X.L.; Wang, L.; et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet. Med. 2006, 23, 623–628. [CrossRef] [PubMed]

17. Codo, A.C.; Davanzo, G.G.; Monteiro, L.B.; de Souza, G.F.; Muraro, S.P.; Virgilio-da-Silva, J.V.; Prodonoiff, J.S.; Carrega, V.C.; de Biagi Junior, C.A.O.; Crunfli, F.; et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α-glycolysis-dependent axis. Cell Metab. 2020, 32, 437-446.e5. [CrossRef] [PubMed]

18. Drucker, D.J. Coronavirus infections and type 2 diabetes–shared pathways with therapeutic implications. Endocr. Rev. 2020, 41, 457–470. [CrossRef]

19. Gianchandani, R.; Esfandiari, N.H.; Ang, L.; Iyengar, J.; Knotts, S.; Choksi, P.; Pop-Busui, R. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes 2020, 69, 2048–2053. [CrossRef]

20. Pal, R.; Banerjee, M.; Yadav, U.; Bhattacharjee, S. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature. Diabetes Metab. Syndr. 2020, 14, 1563–1569. [CrossRef]
21. Knight, S.R.; Ho, A.; Pius, R.; Buchan, I.; Carson, G.; Drake, T.M.; Dunning, J.; Fairfield, C.J.; Gamble, C.; Green, C.A.; et al. Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Development and validation of the 4C Mortality Score. *BMJ* 2020, 370, m3339. [CrossRef]  

22. Guo, W.; Li, M.; Dong, Y.; Zhou, H.; Zhang, Z.; Tian, C. Diabetes Is a Risk Factor for the Progression and Prognosis of COVID-19. *Diabet. Metab. Res. Rev.* 2020, 36, e3319. [CrossRef]  

23. Casqueiro, J.; Casqueiro, J.; Alves, C. Infections in Patients with Diabetes Mellitus: A Review of Pathogenesis. *Indian J. Endocrinol. Metab.* 2012, 16, S27–S36. [CrossRef]  

24. Peleg, Y.; Weerarathna, T.; McCarthy, J.S.; Davis, T. Common Infections in Diabetes: Pathogenesis, Management and Relationship to Glycaemic Control. *Diabet. Metab. Res. Rev.* 2007, 23, 3–13. [CrossRef] [PubMed]  

25. Albai, O.; Timar, R. The relationship between 1 h glycemia, during oral glucose tolerance test and cardiometabolic risk. *Rom. J. Diabetes Nutr. Metab. Dis.* 2012, 19, 25–32. [CrossRef]  

26. Deng, S.-Q.; Peng, H.-J. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. *J. Clin. Med.* 2020, 9, 575. [CrossRef]  

27. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020, 584, 430–436. [CrossRef]  

28. Wu, C.; Chen, X.; Cai, Y. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern. Med.* 2020, 180, 934–943. [CrossRef]  

29. Kulcsar, K.A.; Coleman, C.M.; Beck, S.E.; Frieman, M.B. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. *JCI Insight.* 2019, 4, e131774. [CrossRef]  

30. Adler, E.M. IL-2 Antagonizes Th17 Differentiation. *Sci. STKE* 2007, 2007, tw103. [CrossRef]  

31. Muniyappa, R.; Gubbi, S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am. J. Physiol. Metab.* 2020, 318, E736–E741. [CrossRef]  

32. Tang, X.; Du, R.H.; Wang, R.; Cao, T.Z.; Guan, L.L.; Yang, C.Q.; Zhu, Q.; Hu, M.; Li, X.Y.; Li, Y.; et al. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. *Chest* 2020, 158, 195–205. [CrossRef] [PubMed]  

33. Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang, H.; Wang, T.; Zhang, X.; Chen, H.; Yu, H.; et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J. Clin. Investig.* 2020, 130, 2620–2629. [CrossRef] [PubMed]  

34. Teuwen, L.A.; Geldhof, V.; Pasut, A.; Carmeliet, P. COVID-19: The vasculature unleashed. *Nat. Rev. Immunol.* 2020, 20, 389–391. [CrossRef] [PubMed]  

35. Imai, Y.; Kuba, K.; Neely, G.G.; Yaghubian-Malhami, R.; Perkmann, T.; van Loo, G.; Ermolaeva, M.; Veldhuizen, R.; Leung, Y.H.; Wang, H.; et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. *Cell* 2008, 133, 235–249. [CrossRef] [PubMed]  

36. Shen, Y.; Moriyama, M.; Chang, M.F.; Ichinohe, T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. *Front. Microbiol.* 2019, 10, 50. [CrossRef] [PubMed]  

37. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* 2020, 395, 1054–1062. [CrossRef]  

38. Wang, S.; Ma, P.; Zhang, S.; Song, S.; Wang, Z.; Ma, Y.; Xu, J.; Wu, F.; Duan, L.; Yin, Z.; et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: A multi-centre. *Diabetologia* 2020, 63, 2102–2111. [CrossRef]